Glucose & Insulin

A New Combination Treatment Could Become the Standard T2 Diabetes

A study in Diabetes Care showed that patients with poorly controlled type 2 diabetes who received a combination of exenatide and pioglitazone had a threefold lower rate of hypoglycemia, a one-percentage-point greater reduction in A1C and less weight gain than those in the basal-bolus insulin therapy group.

How Afrezza Inhaled Insulin Makes My Life Better

Afrezza, invented by MannKind, a Connecticut-based pharmaceutical company, is the only inhalable insulin in existence. It’s actually been on the market once before. When it was first launched, about a decade ago, the apparatus to take the insulin was so giant and ill conceived that some likened it to a bong. The new inhaler is […]

Diabetes Tech ‘Spectations for 2017

We’ve been listening to earnings calls and talking with company execs, industry insiders and PR teams to get a sense of what else is on the horizon, compiled in the following report.

2016: A Pivotal Year for Closed Loop/Automated Insulin Delivery

In September, the FDA approved the first hybrid closed-loop system for automating insulin delivery to reduce both highs and lows: Medtronic’s MiniMed 670G system including the latest Guardian Sensor 3 CGM. The milestone approval came after an unexpectedly fast three-month FDA review, and just four months after Medtronic reported positive data from its three-month home […]

Bluetooth insulin dose device helps users keep track of their injections

A new Bluetooth insulin dose tracker, called Insulog, can be fitted onto most existing insulin pens to prevent dose errors in people with type 1 diabetes and insulin-treated type 2 diabetes. The device, created by a Tel Aviv-based startup, is the object of an online crowdfunding campaign recently launched on Indiegogo.

Device ‘Hassle’ Deters Use in Some Type 1 Diabetes Patients

Perception of “hassle” is the most common modifiable barrier keeping people with type 1 diabetes from choosing to wear insulin pumps and continuous glucose monitors (CGMs), new research indicates.

6 New Diabetes Products to Look for in 2017

We’ve rounded up descriptions of some of the most exciting diabetes products expected to hit the market in 2017, followed by an approximate timeframe of when they’ll become available to the public. Sure, what we really want is a cure in 2017, but we’ll take improved quality of life, thanks to new devices and tech, […]

DiabetesMine – On Pharma and Employers in the Insulin Affordability Crisis

We reported earlier this week about a landmark roundtable gathering of diabetes advocates and industry leaders in Washington D.C. to address the complex problem of insulin affordability and access here in the U.S.

Are PBMs Driving Up The Price of Insulin?

PBMs are organizations commonly understood to be the “middle men” in the chain of distribution of prescription drugs and medical devices from the manufacturers to the places where those products are dispensed or purchased through an insurance carrier or a prescription purchase plan. They are also considered the organizations to which health insurance carriers outsource […]

Dexcom’s G6 Sensor Shines in Early Accuracy Study

Earlier this month, Dexcom shared compelling new details on its longer-wear, less calibration G6 sensor and its partnership with Verily to develop a bandage-like continuous glucose monitoring (CGM) device. The G6 sensor is expected to launch in 2018, while the first-gen Verily sensor will launch in late 2018, with a second-gen version coming as early […]

MannKind Markets Afrezza to People with Type 1 Diabetes

The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on diabetics being afraid of needles and more on its clinical advantages over existing insulin.

Novo Nordisk Kills Off Oral Insulin Project

Many in the Type 1 diabetes community wish for two things: lower insulin prices and non-injectable insulin. Now, there’s evidence that the former may have killed off the latter. According to a Fierce Biotech report, Novo Nordisk announced in an October 31st earnings call that it is halting research and development efforts aimed at creating […]

ASweetLife – Until There’s a Diabetes Cure, We Need Better Tools

With the surprising announcement this month that the FDA had cleared the way for Medtronic’s 670G hybrid system, sometimes referred to as an artificial pancreas, most people with diabetes were swinging their pump tubing with glee or juggling their (safety-capped) syringes in delight. And with good reason. We are on the cusp of a flood […]

Donald Trump and Diabetes Policy: What We Know Right Now

Donald Trump’s electoral college win has already had a ripple effect within diabetes care circles. As he’s been putting together an administration, it’s still been hard to predict where his administration will land on issues that affect people with diabetes. Less than a week after the election, already his positions on health care and health […]

Sanders, Cummings Ask Justice Department to Investigate Insulin Prices

Vermont Senator Bernie Sanders and Maryland Representative Elijah Cummings have sent a letter asking the U.S. Department of Justice and the U.S. Federal Trade Commission to open an investigation into whether the three major insulin-manufacturers “have colluded or engaged in anticompetitive behavior in setting their drug prices.”

Diabetes In Control – Making the HbA1c Value More Accurate

John Higgins, M.D., associate professor of systems biology at Harvard Medical School in Boston, along with Dr. Roy Malka and David M. Nathan used an algorithm to analyze blood glucose levels through HbA1c testing. “This enabled the scientists to account for variations in the age of blood cells among different people,” Higgins told Diabetes in […]

FDA Finalizes New Guidelines for Better Glucose Meter Accuracy

On Oct. 11, the regulatory agency issued two sets of guidance, laying out new standards for meters used in clinical settings and also for personal home-use meters. They officially took effect that same day. These guidelines have been many years in the making. The patient and healthcare communities have been voicing concerns about inaccuracy for […]

Why You Still Have to Bolus with the First Artificial Pancreas

There has been vocal criticism among some in the Type 1 diabetes community that the 670G is not automated enough to be considered an artificial pancreas. For example, users of the pump system will still have to bolus for meals. Dr. Kowalski said that there is still more work to be done on developing the […]

Abbott’s FreeStyle Libre Pro Professional CGM System Receives FDA Approval

The US Food and Drug Administration (FDA) approved Abbott’s FreeStyle Libre Pro on September 28 after more than a year of review. The professional continuous glucose monitoring (CGM) system will be made available to US healthcare providers later in Fall 2016.

Aerobic exercise has health benefits for type 1 diabetes patients on insulin pumps

The results of the clinical study, carried out by American and Italian researchers, focused on middle-aged patients treated with insulin pump therapy. They showed a variety of health benefits for those who took part in aerobic exercise, including improved metabolic control, reduced insulin requirements and less hyperglycemic events.